Drugs / AT7519
AT7519
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02503709 | Sep 2016 → Aug 2020 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00390117 | Jan 2007 → Mar 2012 | cancer of unknown primary site, lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01183949 | Nov 2010 → Dec 2014 | plasma cell myeloma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01652144 | Sep 2012 → Dec 2014 | mantle cell lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01627054 | Aug 2012 → Mar 2014 | B-cell chronic lymphocytic leukemia | NCIC Clinical Trials Group | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2010-11-11 | Astex Pharmaceuticals, Inc. | Results Encouraging Data from Phase I Studies of Astex’s Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting astx.com ↗
The data demonstrate that AT7519 is safe and well tolerated with nine of twenty-nine patients treated at four dose levels having stable disease ranging from 2.5 to 11.1 months. |
| 2009-04-14 | Astex Pharmaceuticals, Inc. | Results Astex Reports Positive Clinical Biomarker Data from its Phase I study on CDK Inhibitor AT7519 at the AACR Annual Meeting 2009 astx.com ↗
Results to be reported at this meeting demonstrate that direct inhibition of CDK was observed in skin biopsies or serum samples at all doses during the escalation phase. |
| 2008-12-01 | Astex Pharmaceuticals, Inc. | Results Astex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference astx.com ↗
Data will also be presented by collaborating scientists from the Arizona Cancer Center showing that AT7519 has a cytotoxic effect on tumour samples from patients with chronic lymphocytic leukaemia (CLL). |
| 2008-05-28 | Astex Pharmaceuticals, Inc. | Results Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting astx.com ↗
The results of this study demonstrate evidence of tumour shrinkage and biological activity in patients with advanced cancer treated with AT7519. |
| 2005-06-27 | Astex Pharmaceuticals, Inc. | Regulatory Astex announces IND approval for novel cancer drug AT7519 astx.com ↗
Astex, the fragment-based drug discovery and development company, today announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. |
| 2005-05-23 | Astex Pharmaceuticals, Inc. | Regulatory Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months astx.com ↗
Astex, the fragment-based drug discovery and development company, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. |
All press releases naming this drug 9 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT7519 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503709 ↗ |
| Known as | AT7519M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627054 ↗ |
| Known as | CDKI AT7519 | “Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter).” NCT02503709 ↗ |
| Action | Inhibit | “AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs).” PMID 25393368 ↗ Nov 2014 |
| Modality | Small molecule | “AT7519 is a small-molecular inhibitor of multiple cyclin-dependent kinases (CDKs).” PMID 25393368 ↗ Nov 2014 |
| Route | Intravenous | “given as 1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks.” PMID 25393368 ↗ Nov 2014 |